

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Everolimus with exemestane for treating HER2-negative hormone-receptor-positive breast cancer after endocrine therapy (review of TA295) [ID965]

Provisional matrix of consultees and commentators

| Consultees | Commentators (no right to submit or appeal) |
|---|---|
| <p><u>Company</u></p> <ul style="list-style-type: none"> • Novartis (everolimus) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Black Health Agency • Breast Cancer Care • Breast Cancer Now • Breast Cancer UK • Cancer Black Care • Cancer Equality • Haven • HAWC • Helen Rollason Cancer Charity • Independent Cancer Patients Voice • Macmillan Cancer Support • Maggie's Centres • Marie Curie Cancer Care • Muslim Council of Britain • South Asian Health Foundation • Specialised Healthcare Alliance • Tenovus Cancer Care • Women's Health Concern <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Cancer Physicians • British Geriatrics Society • British Institute of Radiology • British Psychosocial Oncology Society • Cancer Research UK • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Radiologists • Royal Pharmaceutical Society • Royal Society of Medicine • Society and College of Radiographers • UK Health Forum • United Kingdom Clinical Pharmacy Association • United Kingdom Oncology Nursing | <p><u>General</u></p> <ul style="list-style-type: none"> • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare Products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Scottish Medicines Consortium <p><u>Comparator companies</u></p> <ul style="list-style-type: none"> • Accord Healthcare (exemestane) • Aurobindo Pharma (tamoxifen) • Allergan (exemestane) • Pfizer (exemestane) • Rosemont Pharmaceuticals (tamoxifen) • Zentiva UK (exemestane) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Against Breast Cancer • Breast Cancer Hope • Breast Cancer Research Trust • Cochrane Breast Cancer Group • Institute of Cancer Research • MRC Clinical Trials Unit • National Cancer Research Institute • National Cancer Research Network • National Institute for Health Research • Pro-Cancer Research Fund <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales |

| | |
|---|--|
| <p>Society</p> <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • NHS Blackburn with Darwen CCG • NHS East Lancashire CCG • NHS England • Welsh Government | |
|---|--|

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology are invited to prepare a submission dossier, can respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical specialists and/or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary. All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.